Cargando…
Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics
Since 2013 next-generation sequencing (NGS) targeting genes mutated in diffuse gliomas is part of routine diagnostics in our institute. In the present report, we evaluate the use of this custom tailored NGS platform on 434 samples. The NGS panel assesses mutations in ATRX, CIC, EGFR, FUBP1, NOTCH1,...
Autores principales: | Synhaeve, Nathalie E., van den Bent, Martin J., French, Pim J., Dinjens, Winand N. M., Atmodimedjo, Peggy N., Kros, Johan M., Verdijk, R., Dirven, Clemens M. F., Dubbink, Hendrikus J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251173/ https://www.ncbi.nlm.nih.gov/pubmed/30470264 http://dx.doi.org/10.1186/s40478-018-0633-y |
Ejemplares similares
-
Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma
por: Wijnenga, Maarten M. J., et al.
Publicado: (2018) -
Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups
por: Wijnenga, Maarten M J, et al.
Publicado: (2019) -
Mitochondrial D310 mutation as clonal marker for solid tumors
por: Geurts-Giele, Willemina R. R., et al.
Publicado: (2015) -
MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation
por: Groenendijk, Floris H., et al.
Publicado: (2010) -
Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples
por: Mankor, Joanne M., et al.
Publicado: (2020)